Idiopathic Pulmonary Fibrosis
-
Investigators Debut Data from Breaking Clinical Trials in Pulmonary Medicine
on
Read more: Investigators Debut Data from Breaking Clinical Trials in Pulmonary MedicineResearchers shared results from four impactful clinical trials for the first time during “Breaking News: Clinical Trial Results in Pulmonary Medicine” on Sunday at ATS 2026 Orlando. The studies offered insights into pulmonary arterial hypertension, idiopathic pulmonary fibrosis, obstructive sleep apnea, and more.
-
Amberson Lecturer Outlines Promise of Leveraging Cyclic AMP in Fibrosis Resolution Research
on
Read more: Amberson Lecturer Outlines Promise of Leveraging Cyclic AMP in Fibrosis Resolution ResearchMarc Peters-Golden, MD, delivered the J. Burns Amberson Lecture on Sunday at ATS 2026 Orlando. Dr. Peters-Golden shared the rationale and mechanistic basis for cyclic adenosine monophosphate-elevating therapies and discussed future possibilities for similar approaches. He also reflected on personal lessons learned across his distinguished career.
-
ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPF
on
Read more: ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPFThe ATS 2026 International Conference will spotlight a wide range of recent investigative and clinical advances in the treatment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), including the development of nerandomilast, the first FDA-approved therapy for IPF in over a decade. Susan K. Mathai, MD, spoke with ATS Conference News to preview…
-
ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD Treatments
on
Read more: ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD TreatmentsTreating pediatric patients with ILD or IPF can require unique treatment considerations and innovations compared with the treatment of adult populations. The relative rarity of pediatric patients with ILD reveals an urgent need for education among pediatric subspecialty providers and primary care physicians about how to diagnose and treat these diseases in collaboration with pediatric…
-
ILD and IPF Lineup at ATS 2026 Orlando
on
Read more: ILD and IPF Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating ILD and IPF.